Breast Cancer Foundation NZ
FINER
Advanced Breast Cancer clinical trials for ER+
This clinical trial aims to find out if a new drug, ipatasertib, along with standard treatment fulvestrant will keep advanced ER+/HER2- breast cancer under control for longer.
The FINER clinical trial aims to find out if a new drug, ipatasertib, along with standard treatment fulvestrant will keep cancer under control for longer in patients with advanced ER+ and HER2- breast cancer.
Who is it for?
Those whose advanced ER+/HER- breast cancer has progressed after 'first line' treatment with a CDK 4/6 inhibitor (such as Ibrance) and an aromatase inhibitor (anastrozole, exemestane, letrozole).
Study details
Participants in this study will be randomised into two arms, one that will receive ipatasertib and fulvestrant and the other, a placebo and fulvestrant.
Participants will be followed up in clinic regularly throughout the study and then every 12 weeks once treatment has ended.
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.